Calcitonin gene-related peptide inhibits early B cell development in vivo

J Leukoc Biol. 2007 Mar;81(3):802-8. doi: 10.1189/jlb.0306229. Epub 2006 Nov 16.

Abstract

Recent in vitro studies suggest that calcitonin gene-related peptide (CGRP) inhibits early B cell differentiation; however, there is no evidence in the intact animal for a role for CGRP in B cell development. Here, we show that in vivo treatment of mice with CGRP reduces the number of IL-7 responsive B cell progenitors in bone marrow. A single CGRP treatment reduces IL-7-responsive B cell progenitors by up to 40% for up to 72 h. The reduction is dose-dependent and can be blocked by a CGRP receptor antagonist, CGRP(8-37). CGRP in serum following injection is highly elevated at 30 min but returns to basal levels by 4 h, suggesting that a single injection of CGRP has long-lasting effects on B cell development. This report provides the first direct in vivo evidence that CGRP, a neuropeptide with multiple effects on mature lymphocytes, also plays a regulatory role in early B cell development in the bone marrow.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • B-Lymphocytes / cytology*
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / immunology
  • Bone Marrow / immunology
  • Calcitonin Gene-Related Peptide / administration & dosage
  • Calcitonin Gene-Related Peptide / blood
  • Calcitonin Gene-Related Peptide / pharmacology*
  • Cell Proliferation / drug effects
  • Colony-Forming Units Assay
  • Injections, Intravenous
  • Interleukin-7 / antagonists & inhibitors
  • Interleukin-7 / immunology
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Stem Cells / cytology
  • Stem Cells / drug effects
  • Stem Cells / immunology
  • Structure-Activity Relationship

Substances

  • Interleukin-7
  • Calcitonin Gene-Related Peptide